Learn About Gastroesophageal Junction Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Rhode Island Hospital
Howard Safran is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Dr. Safran is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Pancreatic Cancer, Gastroesophageal Junction Cancer, Colorectal Cancer, Stomach Cancer, and Pancreaticoduodenectomy.
Duke Cancer Center
I decided to go to medical school during the early part of college and then never really looked back. I enjoyed every discipline while I was in medical school and had a difficult time selecting a specialty, until I did a rotation in Hematology/Oncology. After observing the relationships that oncologists develop with patients and their families, I knew that medical oncology was the right place for me. Getting to know my patients and their families and helping them achieve their goals, despite a cancer diagnosis, has become extremely important to me. I also enjoy working as part of a multidisciplinary team to make sure that patients get the most comprehensive care possible. When I am not working, I enjoy spending time with family, reading, and running. Dr. Uronis is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Gastroesophageal Junction Cancer, Colorectal Cancer, Pancreatic Cancer, Stomach Cancer, and Pancreaticoduodenectomy.
Eric Van Cutsem practices in Leuven, Belgium. Mr. Van Cutsem is rated as an Elite expert by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Colorectal Cancer, Gastroesophageal Junction Cancer, Stomach Cancer, Hepato-Pancreato-Biliary Surgery, and Endoscopy.
Summary: The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Summary: The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.